Oncology Data Abstraction: Fixing the Denial Rate at Intake, Not on Appeal
Oncologists report denial rates of 30 to 40 percent on claims submitted to commercial payers, high enough that some say they hold their breath every time they submit one (Oncology News Central). A separate review of appealed genetic-testing denials from 2019 to 2023 found 46 percent were overturned on independent review, and cancer accounted for 70 percent of that dataset. The claims were valid. The documentation to prove it either wasn’t captured, or wasn’t captured where anyone could find it in time.
What Oncology Data Abstraction Has Always Meant
Oncology data abstraction has traditionally meant a certified tumor registrar reading a pathology report, a staging note, and a treatment summary, then translating that into the structured fields a cancer registry requires. It supports accreditation, quality reporting, and research. It is thorough, and it happens after the fact, once treatment is already underway.
The same documents that feed registry reporting also determine whether a claim gets paid. When the detail that would have supported medical necessity is missing at the point of abstraction, it stays missing when the claim goes out.
The Same Gap Shows Up Later, as a Denial
By the time a claim gets denied, the record it was built from was already incomplete. Most oncology denials trace back to missing or inconsistent documentation, not an error in the diagnosis or the treatment plan itself.
The claims were valid. The documentation to prove it just wasn’t there when it needed to be.
Why Downstream Denial Management Doesn’t Close the Gap
Denial management tools route, categorize, and speed up appeals once a claim already failed. That work matters, but it starts after the gap has already cost time and revenue. Fixing the rate itself means catching the missing detail before the claim is built, not getting faster at appealing it after.
Closing the Gap at Intake
Cures® is the Clinical Clarity Engine for healthcare, assembling and structuring patient medical records into decision-ready data. xCures set its validation standard in oncology, the hardest case in medicine, before extending it across every clinical domain. That standard is what closes this specific gap.
The Clinical Clarity Engine works through three products, in this order:
Decision-Ready Checklists match a payer’s coverage criteria against what the patient’s record already contains, at the point of abstraction rather than after a denial
Automated Patient History assembles the longitudinal record automatically across pathology reports, treatment summaries, and follow-up notes
Evidence Grade Data is built on 3,000+ validated extractors, and every extracted answer maps back to the exact source document and page
A record abstracted once, correctly, can support the registry, the claim, and the next clinical decision, instead of three separate manual passes.
What the Numbers Show
xCures processes more than 1.5 million documents per day, across more than 550,000 care locations.* Extractors are validated against clinical review, not the output itself, giving 99.7 percent combined accuracy across 200-plus comorbidity assessments.* None of this replaces a registrar’s judgment. It removes the manual gap between what the record contains and what the claim needs.
*Results based on a retrospective analysis of a defined historical dataset and do not guarantee future performance.
Where This Falls Short
Closing the documentation gap at intake reduces the denials that trace back to missing information. It does not eliminate payer policy disputes, coverage decisions on experimental treatments, or every edge case a complex oncology claim can run into. Some of that 30 to 40 percent will always need a human reviewer and a real appeal.
See what xCures would have caught before your last oncology denial.
30-min demo, no prep required.
Frequently asked.
Why do oncology claims get denied even when the diagnosis and treatment were appropriate?
Most trace back to missing or incomplete documentation captured during abstraction, not an error in the clinical decision itself.
What is oncology data abstraction?
It’s the process of pulling structured data, diagnosis, staging, treatment, and outcomes, out of a cancer patient’s record. It has traditionally supported registry reporting. xCures automates the same underlying extraction so it can also support the claim, not just the registry.
How is this different from oncology denial management software?
Denial management tools work after a claim is already denied, routing and speeding up appeals. xCures works upstream, closing the documentation gap before the claim is built.
What proof does xCures have that this works?
xCures processes more than 1.5 million documents per day, with extractors validated against clinical review, giving 99.7 percent combined accuracy across 200-plus comorbidity assessments.* Results based on a retrospective analysis of a defined historical dataset and do not guarantee future performance.
Does this replace our appeals process?
No. It reduces how often you need one. Payer policy disputes and coverage decisions on experimental treatments will still need a human reviewer.